Drug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures is a research paper published in Cancers (2021). On theSindex it has a DataRank of 0. It has been cited 28 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: U01 CA238720
Israel Science Foundation
Grant: 1961/19
National Institutes of Health
Grant: 3U01CA238720-05S1
Identification of adaptive response mechanisms in breast cancer by information theory and proteomics
FWCI
1.94
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 2 of Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistance
Additional file 2 of Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistance
Additional file 1 of Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer
Additional file 1 of Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer
Additional file 2 of Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer
Additional file 2 of Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer
Additional file 3 of Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer
Additional file 3 of Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer